SAN DIEGO--(BUSINESS WIRE)--Dec. 21, 2005--Maxim Pharmaceuticals, Inc. (NASDAQ:MAXM)(SSE:MAXM) announced today that the proposal to approve and adopt the Agreement and Plan of Merger between EpiCept Corporation and Maxim and to approve the merger was approved by the holders of a majority of the outstanding shares of Maxim at its Special Meeting of Stockholders. EpiCept's stockholders had previously voted to approve the merger agreement and the issuance of the EpiCept common stock to Maxim's stockholders in the merger. Maxim expects to close the merger transaction in January 2006.
